Topic: drug reimbursement
Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
In a first, Pfizer promises reimbursement of up to 33.5% of Ibrance costs for eligible Chinese breast cancer patients.
Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its next-generation cell and gene therapies.
Amgen declared the launch of migraine drug Aimovig an unqualified success, but analysts weren't quite ready to buy in to the euphoria.
AbbVie is counting on oncology med Venclexta to drive serious growth, especially as biosimilars to top seller Humira advance. But England has other plans.
Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
Back in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision.
A couple of drugmakers are celebrating this week after favorable decisions from England’s cost watchdog.